Roche’s Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set to consolidate its position.
Itovebi (inavolisib) has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, moving it up the treatment pathway ahead of Novartis’ rival PIK3 inhibitor Piqray/Vijoice (alpelisib) which has been cleared since 2019 as a second-line therapy and is not being developed as a…